Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Clinical trial NCT06439485 · RECRUITING

Trial details

NCT number

NCT06439485

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2024-11-19

Primary completion

2028-02-22

Enrollment

25

View on ClinicalTrials.gov